Trials / Completed
CompletedNCT03187314
Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer
Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Hangzhou Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radiation | RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210 |
| DRUG | SHR-1210 | SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes. |
Timeline
- Start date
- 2017-06-14
- Primary completion
- 2019-06-30
- Completion
- 2019-06-30
- First posted
- 2017-06-14
- Last updated
- 2020-08-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03187314. Inclusion in this directory is not an endorsement.